These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 19124524)

  • 1. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors.
    Westhovens R; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Helfrick R; Bathon J
    Ann Rheum Dis; 2009 Dec; 68(12):1870-7. PubMed ID: 19124524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
    Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R
    Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.
    Kremer JM; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Westhovens R; Li T; Zhou X; Becker JC; Aranda R; Peterfy C; Genant HK
    Ann Rheum Dis; 2011 Oct; 70(10):1826-30. PubMed ID: 21893583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial.
    Kremer JM; Peterfy C; Russell AS; Emery P; Abud-Mendoza C; Sibilia J; Becker JC; Westhovens R; Genant HK
    J Rheumatol; 2014 Jun; 41(6):1077-87. PubMed ID: 24786925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M
    Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
    Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Li T; Ge Z; Becker JC; Westhovens R
    Ann Intern Med; 2006 Jun; 144(12):865-76. PubMed ID: 16785475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
    Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW
    Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).
    Emery P; Durez P; Dougados M; Legerton CW; Becker JC; Vratsanos G; Genant HK; Peterfy C; Mitra P; Overfield S; Qi K; Westhovens R
    Ann Rheum Dis; 2010 Mar; 69(3):510-6. PubMed ID: 19933744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
    Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R
    Arthritis Rheum; 2013 Jan; 65(1):28-38. PubMed ID: 23169319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate.
    Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechiński J; Li T; Teng J; Becker JC; Westhovens R
    Arthritis Rheum; 2008 Apr; 58(4):953-63. PubMed ID: 18383390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study.
    Westhovens R; Kremer JM; Moreland LW; Emery P; Russell AS; Li T; Aranda R; Becker JC; Qi K; Dougados M
    J Rheumatol; 2009 Apr; 36(4):736-42. PubMed ID: 19273451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
    Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
    Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
    Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
    Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis.
    Schiff M; Bessette L
    Clin Rheumatol; 2010 Jun; 29(6):583-91. PubMed ID: 20099018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.